Health Canada Approves Augurex’s Novel SPINEstat™ for Axial Spondyloarthritis
Augurex Life Sciences Corp., a company specialising in autoimmune diagnostic tools, has received approval from Health Canada for its new blood test, SPINEstat™. The test is the first of its kind to support the diagnosis of axial spondyloarthritis (axSpA), a chronic inflammatory condition that mainly affects the spine.
SPINEstat™ is classified as a Class II medical device and works by detecting auto-antibodies to the 14-3-3eta protein. This biomarker offers doctors an objective way to help identify axSpA, a disease that is often difficult to diagnose in its early stages.
AxSpA affects around 400,000 people in Canada and typically begins before the age of 45. Symptoms often include long-term back pain, which is a common issue affecting nearly 30% of adults in North America. Because of this, axSpA is often mistaken for other causes of back pain. The average time from the first symptoms to diagnosis can take between seven and ten years.
The introduction of SPINEstat™ aims to reduce this delay by helping healthcare professionals distinguish axSpA from other types of back pain earlier and more accurately. This could lead to quicker access to treatment and better health outcomes for those living with the condition.
This latest approval marks a significant development in the area of autoimmune diagnostics and strengthens Augurex’s role in supporting clinicians with more reliable tools for disease detection and management.